Analysts’ Opinions Are Mixed on These Healthcare Stocks: Globus Medical (GMED) and Inogen (INGN)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED) and Inogen (INGN).

Globus Medical (GMED)

Needham analyst David Saxon reiterated a Buy rating on Globus Medical today and set a price target of $82.00. The company’s shares closed last Tuesday at $69.64, close to its 52-week high of $73.05.

According to TipRanks.com, Saxon is a 4-star analyst with an average return of 38.0% and a 87.5% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, NuVasive, and SI-Bone.

Currently, the analyst consensus on Globus Medical is a Moderate Buy with an average price target of $75.78, a 6.8% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $81.00 price target.

See today’s analyst top recommended stocks >>

Inogen (INGN)

Needham analyst Michael Matson assigned a Hold rating to Inogen today. The company’s shares closed last Tuesday at $67.09, close to its 52-week high of $68.41.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 17.2% and a 69.4% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

Inogen has an analyst consensus of Hold.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts